
A review of the neutralizing antibody that was studied in a phase 2/3 trial in outpatients with mild to moderate infections of COVID-19.
A review of the neutralizing antibody that was studied in a phase 2/3 trial in outpatients with mild to moderate infections of COVID-19.
Contagion® radio is here to bring joy with every new antibiotic alert!
Fosfomycin is an attractive potential option because it does not cross-react with other antimicrobials, making it a good choice in patients with extensive drug allergies.
Published: December 23rd 2019 | Updated:
Published: August 5th 2019 | Updated: